Seemingly safer steroid mimics | Science News

Support Science Journalism

Science News is a nonprofit.

Support us by subscribing now.


Seemingly safer steroid mimics

9:57am, June 28, 2001

Doctors rely heavily on the inflammation-reducing steroids called glucocorticoids to treat asthma and arthritis. Chronic treatment with high doses of these drugs, however, can lead to diabetes, bone loss, and growth retardation.

So, researchers at Ligand Pharmaceuticals in San Diego and Abbot Laboratories in Abbot Park, Ill., set out to develop designer glucocorticoids that would mimic the beneficial but not the detrimental effects of the steroids (SN: 10/16/99, p. 252). Tests in cultured human cells and in rats indicate that a new compound called AL-438 meets this goal, they now report.

In arthritic rats, for instance, AL-438 reduces joint swelling and damage as well as a standard glucocorticoid does, says Jeffrey N. Miner of Ligand. Unlike a steroid, however, AL-438 doesn't lead to abnormally high concentrations of sugar in the blood, which indicate an increased risk of diabetes. Miner and his colleagues are still collecting data on the drug's effect on bone loss.

This article is only available to Science News subscribers. Already a subscriber? Log in now.
Or subscribe today for full access.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content